2025-10-03 - Analysis Report
Okay, here's an analysis of Recursion Pharmaceuticals (RXRX), incorporating the data you provided:

## RXRX Analysis: Recursion Pharmaceuticals Inc.

**Company Overview:** Recursion Pharmaceuticals is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to discover, develop, and commercialize novel therapeutics.

### 1. Performance vs. S&P 500 (VOO)

*   **RXRX Cumulative Return:** -23.20%
*   **VOO Cumulative Return:** 39.55%
*   **Absolute Divergence:** -62.75% (RXRX underperformed VOO by this amount)
*   **Relative Divergence:** 1.0 (Indicates RXRX's performance relative to its own historical divergence range).

**Analysis:** RXRX has significantly underperformed the S&P 500 over the covered period. The negative divergence is substantial, suggesting a significant performance gap.  The relative divergence of 1.0 implies that this underperformance is at the lower end of RXRX's historical performance range compared to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha   | Beta   | Cap(B) |
|------------|---------|-------|---------|--------|--------|
| 2021-2023  | 22.0%  | 81.0% | 26.0%  | -0.2  | 4.2    |
| 2022-2024  | 11.0%  | 81.0% | -10.0% | 0.1  | 2.9    |
| 2023-2025  | 19.0%  | 80.0% | -43.0% | 0.1  | 2.1    |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):** The CAGR varies significantly across the different periods, suggesting volatile performance.
*   **MDD (Maximum Drawdown):** The MDD is consistently high (around 80%), indicating substantial risk and potential for significant losses.
*   **Alpha:** Alpha is inconsistent.  While positive for 2021-2023, it is negative for the more recent periods, indicating underperformance relative to the benchmark.
*   **Beta:** Beta is very low or negative, suggesting low correlation with the market(S&P 500).
*   **Cap:** The decreasing capitalization values are shown.

### 2. Recent Price Action

*   **Current Price:** 4.83
*   **Last Market Data:** Price: 5.52, Previous Close: 5.1, Change: +8.24%
*   **5-day Moving Average:** 4.809
*   **20-day Moving Average:** 4.7547
*   **60-day Moving Average:** 5.2607

**Analysis:**

*   The price increase of 8.24% from the previous close indicates a potentially volatile move.
*   The current price is above both the 5-day and 20-day moving averages, which could be interpreted as a short-term bullish signal. However, it's still below the 60-day moving average.

### 3. Indicators & Expected Return

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 54.01
*   **PPO:** 0.51
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (136 shares - Very Safe - MRI:0.90)
*   **Recent (20-day) Relative Divergence Change:** -0.4 (Short-term Decline)
*   **Expected Return (%):** -440.9%

**Analysis:**

*   The high MRI suggests that the model perceives a favorable risk/reward profile.
*   RSI is neutral (around 50), not indicating overbought or oversold conditions.
*   PPO is slightly positive, hinting at potential upward momentum.
*   The negative change in relative divergence indicates recent underperformance compared to the S&P 500.
*   The extremely negative expected return suggests a very pessimistic long-term outlook based on the model.

### 4. Recent News & Events

*   **Needham Reiterates a Buy:** Positive analyst coverage.
*   **Jim Cramer's Skepticism:** Concerns about proof of concept.
*   **Motley Fool's Long-Term View:**  Analysis of RXRX's potential in 5 years.
*   **Motley Fool's Risk Assessment:**  Concerns about the stock's risk profile.
*   **Nvidia's AI Investment:**  Broader context of AI investment trends (potentially relevant to RXRX).
*   **Short Squeeze Potential:** Discussion of short squeeze possibilities and AI impact.

**Analysis:** The news is mixed. While some analysts are positive, there are concerns about the company's business model and risk. The AI narrative is a recurring theme, which could be a catalyst for the stock.

### 4-2) Analyst Opinions

*   **Mean Recommendation:** Neutral (insufficient data to determine)
*   **Target Price (avg/high/low):** 6.47 / 10.00 / 3.00

**Analysis:**  The average target price suggests potential upside from the current price, but the range is wide, indicating uncertainty among analysts.

### 5. Recent Earnings Analysis

| 날짜       | EPS    | 매출      |
|------------|--------|-----------|
| 2025-08-05 | -0.41  | 0.02 B$  |
| 2025-05-05 | -0.5  | 0.01 B$  |
| 2024-11-06 | -0.34  | 0.03 B$  |
| 2024-08-08 | -0.4  | 0.01 B$  |
| 2025-08-05 | -0.4  | 0.01 B$  |

**Analysis:**

*   Recursion Pharmaceuticals has not demonstrated profit from 2024 to 2025.
*   The company has consistently reported negative EPS values.
*   Revenue generation has been inconsistent.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue  | Profit Margin |
|--------------|----------|---------------|
| 2025-06-30   | $0.02B   | -5.54%        |
| 2025-03-31   | $0.01B   | -47.31%       |
| 2024-12-31   | $0.00B   | -183.62%      |
| 2024-09-30   | $0.03B   | 53.69%        |
| 2024-06-30   | $0.01B   | 36.14%        |

**Capital and Profitability:**

| Quarter      | Equity   | ROE      |
|--------------|----------|----------|
| 2025-06-30   | $0.92B   | -18.70%  |
| 2025-03-31   | $0.93B   | -21.68%  |
| 2024-12-31   | $1.03B   | -17.29%  |
| 2024-09-30   | $0.52B   | -18.27%  |
| 2024-06-30   | $0.58B   | -16.69%  |

**Analysis:**

*   **Revenue:** The company's revenue stream is inconsistent with relatively small values.
*   **Profit Margin:**  Profit margins are mostly negative, indicating a lack of profitability.
*   **Equity:** Equity has been volatile.
*   **ROE:**  The consistently negative ROE reflects the lack of profitability and inefficient use of equity.

### 7. 종합 Summary

Recursion Pharmaceuticals (RXRX) is a high-risk, high-reward stock. It has underperformed the S&P 500 significantly, and its financial performance is currently weak, characterized by negative earnings, inconsistent revenue, and negative profit margins. The high maximum drawdown also reflects a risk of high losses.

However, the company is operating in the potentially lucrative field of AI-driven drug discovery. Recent analyst coverage is mixed, but some see potential upside. The MRI suggests a favorable risk/reward profile, but the extremely negative expected return calculated by the model is a major red flag.

**In conclusion, an investment in RXRX is highly speculative and should only be considered by investors with a high-risk tolerance and a strong belief in the company's long-term potential.** The recent price increase is a positive sign, but it is important to consider the overall negative trend and financial performance. The mixed analyst opinions and Jim Cramer's skepticism should also be taken into account. Furthermore, investors need to consider the news headlines when making a decision.
